Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04722822 · ClinicalTrials.gov registry record · NA
The HPV 9-10 Trial: Early Initiation of HPV Vaccination
A NA study of Hpv, sponsored by University of Colorado, Denver.
- Recruiting
- Registry status
- NA
- Development phase
- 3,100
- Enrollment target
- 2
- Study locations
NCT04722822: Recruiting NA study of Hpv, sponsored by University of Colorado, Denver.
NCT04722822 is a NA study of Hpv that is actively recruiting participants, run by University of Colorado, Denver. The registered enrollment target is 3,100 participants, above the 2,112-participant average among 24 other Hpv trials with a reported enrollment target (47% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04722822, a NA study of Hpv, is actively recruiting participants, sponsored by University of Colorado, Denver.
- RECRUITING
- Registry status
- NA
- Development phase
- 3,100 participants
- Enrollment target
- 2
- Study locations
Study Summary
Every year, thousands of Americans die from cancers related to human papillomavirus (HPV). The vast majority of those deaths could be prevented with a safe and effective vaccine, yet many parents choose not have their children vaccinated when it is recommended at age 11 or 12. In this study, we will examine in a randomized trial whether earlier initiation of the vaccine at age 9-10 years will result in less parental refusal and higher rates of full vaccination at younger ages, before early sexual activity begins.
Primary Outcome
The primary outcome will be age at completion of the two dose HPV series. This is a time-to-event outcome, with the event of interest being vaccine completion. Comparisons between the intervention practices and control practices will be made. Practice electronic health records will be used to assess this outcome.
Conditions Studied
Interventions
- BEHAVIORAL (Intervention) Recommending HPV vaccine for patients 9-10 years of age
- BEHAVIORAL (Control) Recommending HPV vaccine for patients 11-12 years of age
Study Locations (2)
California
- University of California at Los Angeles - Los Angeles
Colorado
- University of Colorado - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,100 participants |
| Start Date | 2019-12-23 |
| Est. Completion | 2027-04-01 |
| Phase | NA |
What NCT04722822 shows while recruiting
NCT04722822 is an interventional study that assigns participants to a tested intervention. Its 3,100 participants enrollment target places it among the larger protocols in the corpus, above the 2,112-participant average among 24 other Hpv trials with a reported enrollment target (47% higher).
The record links to 1 condition, with Hpv appearing as the primary indexed condition, and to 2 interventions - of which (Intervention) Recommending HPV vaccine for patients 9-10 years of age is the first listed.
NCT04722822 reports a single indexed study location in California, Colorado.
Frequently Asked Questions
What is clinical trial NCT04722822 about?
NCT04722822 is a clinical study titled "The HPV 9-10 Trial: Early Initiation of HPV Vaccination". Every year, thousands of Americans die from cancers related to human papillomavirus (HPV). The vast majority of those deaths could be prevented with a safe and effective vaccine, yet many parents choose not have their children vaccinated when it is recommended at age 11 or 12. In this study, we will...
What is the current status of trial NCT04722822?
This trial is currently recruiting. It is a NA study. The enrollment target is 3,100 participants. The study started on 2019-12-23. Estimated completion is 2027-04-01.
What conditions does trial NCT04722822 study?
This clinical trial studies the following conditions: Hpv.
What interventions are being tested in trial NCT04722822?
The interventions under investigation include: (Intervention) Recommending HPV vaccine for patients 9-10 years of age (BEHAVIORAL), (Control) Recommending HPV vaccine for patients 11-12 years of age (BEHAVIORAL).
Who is sponsoring clinical trial NCT04722822?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04722822 being conducted?
This trial has 2 study locations across California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hpv
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04722822's enrollment target sits among peer trials
3,100 4th of 24 higher than 21 of 24 other Hpv trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hpv trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PopSci CHW4CervixHealth
RECRUITING · NA
-
Stand Up 2 HPV: Standing Orders to Improve HPV Vaccination
RECRUITING · NA
-
HPV Self-Collection Program
RECRUITING · NA
-
Evaluation of the Q-Pad hrHPV Test System for Identifying Precancer
RECRUITING · NA
-
Prevención en Sus Manos: Feasibility of a Novel Community-Based Strategy to Improve Access to Cervical Cancer Screening
RECRUITING · NA
-
Playing Game to Learn About Children's Vaccine Project
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05051722 · 3,110 participants
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
- NCT05534243 · 3,090 participants · NA
The ED-AWARENESS-2 Trial
- NCT06667700 · 3,082 participants · Phase 3
A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)
- NCT06224205 · 3,150 participants · NA
Digital Detection of Dementia (D Cubed) Studies: D3
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI